Operator
Welcome to the Royal Philips Fourth Quarter and Full Year 2020 Results Conference Call on Monday, January 25, 2021. During the call hosted by Mr. Frans van Houten, CEO; and Mr. Abhijit Bhattacharya, all participants will be in a listen-only mode. [Operator Instructions]
I will now hand the conference over to Mr. Leandro Mazzoni, Head of Investor Relations. Please go ahead, sir.
Leandro Mazzoni
Head of Investor Relations
Good morning, ladies and gentlemen. Welcome to Philips fourth quarter and full year 2020 results conference call. I m here with our CEO, Frans van Houten; and our CFO, Abhijit Bhattacharya. On today s call, Frans will take you through our strategic and financial highlights for the period. Abhijit will then provide more detail on the financial performance. And after that, we will take your questions.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Five-year ILLUMENATE EU RCT and Pivotal study results confirm safety profile of Philips .
Royal PhilipsJanuary 25, 2021 GMT
January 25, 2021
Two major randomized controlled trials (RCTs) show no difference in mortality between patients treated with the Philips Stellarex drug-coated balloon (DCB) and those treated with percutaneous angioplasty (PTA), the current standard of care
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the final, five-year results of two major randomized controlled trials (RCTs) that show no difference in all-cause mortality between patients treated with the Stellarex drug-coated balloon (DCB) and those treated with percutaneous angioplasty (PTA), the current standard of care. Moreover, the studies showed no difference in mortality between the Stellarex DCB and PTA at every 12-month endpoi